The company targeted cost redundancies and facility consolidations to drive EBITDA margins. NuVasive's sales force integration with Globus Medical's robotic systems is progressing well. The FDA warning letter had minimal impact on sales. Globus Medical is confident in the capital equipment environment despite new competitors.